EE03287B1 - T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee - Google Patents

T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee

Info

Publication number
EE03287B1
EE03287B1 EE9600096A EE9600096A EE03287B1 EE 03287 B1 EE03287 B1 EE 03287B1 EE 9600096 A EE9600096 A EE 9600096A EE 9600096 A EE9600096 A EE 9600096A EE 03287 B1 EE03287 B1 EE 03287B1
Authority
EE
Estonia
Prior art keywords
preparation
methods
medicaments
manufacture
pharmaceutical composition
Prior art date
Application number
EE9600096A
Other languages
English (en)
Inventor
C. Makrides Savvas
C. Kung Patrick
Original Assignee
T Cell Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences, Inc. filed Critical T Cell Sciences, Inc.
Publication of EE03287B1 publication Critical patent/EE03287B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
EE9600096A 1994-01-13 1995-01-12 T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee EE03287B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/181,492 US5552300A (en) 1994-01-13 1994-01-13 T cell antigen receptor V region proteins and methods of preparation thereof
PCT/US1995/000408 WO1995019435A2 (en) 1994-01-13 1995-01-12 T cell antigen receptor v region proteins and methods of preparation thereof

Publications (1)

Publication Number Publication Date
EE03287B1 true EE03287B1 (et) 2000-08-15

Family

ID=22664497

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600096A EE03287B1 (et) 1994-01-13 1995-01-12 T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee

Country Status (21)

Country Link
US (1) US5552300A (et)
EP (1) EP0738322A1 (et)
JP (1) JPH10501961A (et)
KR (1) KR100213396B1 (et)
AU (1) AU700661B2 (et)
BR (1) BR9506612A (et)
CA (1) CA2181171A1 (et)
CZ (1) CZ9602009A3 (et)
EE (1) EE03287B1 (et)
FI (1) FI962844L (et)
HU (1) HUT75551A (et)
IL (1) IL112316A0 (et)
LV (1) LV11630B (et)
MX (1) MX9602750A (et)
NO (1) NO962921L (et)
NZ (2) NZ279605A (et)
PL (1) PL181072B1 (et)
SG (1) SG52342A1 (et)
SK (1) SK90696A3 (et)
WO (1) WO1995019435A2 (et)
ZA (1) ZA95261B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US20040229282A1 (en) * 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
AU4188100A (en) 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
WO2004015070A2 (en) 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
CA2530980A1 (en) * 2003-06-19 2005-01-20 Tanox, Inc. Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome
CA2572870A1 (en) * 2004-07-06 2006-01-12 Transpharma Medical Ltd. Delivery system for transdermal immunization
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US20070009542A1 (en) * 2005-07-05 2007-01-11 Galit Levin Method and device for transdermal immunization
EP2258441A3 (en) 2005-09-02 2011-09-21 Intercell USA, Inc. Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs
PT2016414E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
US8606366B2 (en) 2009-02-18 2013-12-10 Syneron Medical Ltd. Skin treatment apparatus for personal use and method for using same
CN102573883A (zh) 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713332A (en) * 1984-01-13 1987-12-15 The Ontario Cancer Institute T cell specific CDNA clone
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
EP0570027B1 (en) * 1984-03-01 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University T cell receptor-specific for antigen polypeptides and related polynucleotides
US4845026A (en) * 1985-12-03 1989-07-04 T Cell Sciences, Inc. Assay systems for detecting cell-free T cell antigen receptor related molecules and the clinical utilities of the assays
US5024940A (en) * 1987-02-19 1991-06-18 T Cell Sciences, Inc. Nucleic acids encoding the delta chain of the T cell antigen receptor
US5185250A (en) * 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
EP0712928A2 (en) * 1987-06-23 1996-05-22 The Board Of Trustees Of The Leland Stanford Junior University T cell antigen receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
ES2062519T5 (es) * 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
CA2032138A1 (en) * 1989-05-02 1990-11-03 Irun R. Cohen Anti-ergotypic t cells for the treatment or prevention of autoimmune diseases and methods of use thereof
CA2072356A1 (en) * 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
EP0725277A3 (en) * 1990-05-01 1996-12-04 Univ Leland Stanford Junior Variable transcripts of T cells as markers for diseases
DE69124518T2 (de) * 1990-08-09 1997-05-15 National Jewish Center For Immunology And Respiratory Medicine, Denver, Col. Herstellung monoklonaler Antikörper gegen menschliches Vbeta T-Zellrezeptorelement unter Verwendung rekombinanter DNA-Vektoren
WO1992013950A2 (fr) * 1991-02-12 1992-08-20 Roussel-Uclaf SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES β DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES
ES2144418T3 (es) * 1991-05-31 2000-06-16 Connetics Corp Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
WO1993006135A1 (en) * 1991-09-23 1993-04-01 Genentech, Inc. Diagnosing and treating autoimmune disorders
US5333487A (en) * 1991-11-15 1994-08-02 Hughes Aircraft Company Spark-excited fluorescence sensor
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor

Also Published As

Publication number Publication date
SG52342A1 (en) 1999-06-22
NZ279605A (en) 1999-01-28
BR9506612A (pt) 1997-09-16
PL319374A1 (en) 1997-08-04
WO1995019435A2 (en) 1995-07-20
LV11630A (lv) 1996-12-20
EP0738322A1 (en) 1996-10-23
FI962844A7 (fi) 1996-08-29
LV11630B (en) 1997-08-20
CA2181171A1 (en) 1995-07-20
AU700661B2 (en) 1999-01-14
FI962844L (fi) 1996-08-29
KR970700772A (ko) 1997-02-12
PL181072B1 (pl) 2001-05-31
NO962921L (no) 1996-09-02
NZ332715A (en) 2000-06-23
JPH10501961A (ja) 1998-02-24
US5552300A (en) 1996-09-03
CZ9602009A3 (en) 1997-12-17
HU9601908D0 (en) 1996-09-30
NO962921D0 (no) 1996-07-11
IL112316A0 (en) 1995-03-30
HUT75551A (en) 1997-05-28
AU1678495A (en) 1995-08-01
SK90696A3 (en) 1997-07-09
KR100213396B1 (ko) 1999-08-02
WO1995019435A3 (en) 1995-08-24
MX9602750A (es) 1997-05-31
FI962844A0 (fi) 1996-07-12
ZA95261B (en) 1995-11-14

Similar Documents

Publication Publication Date Title
EE03287B1 (et) T-raku antigeeni retseptori V-piirkonna proteiinid, nende valmistamismeetodid, nende saamiseks vajalik ekspressioonivektor ning bakteriaalne rakk, neid sisaldav farmatseutiline kompositsioon, nende kasutamine medikamentide tootmisel ning diagnoosimee
EE200000380A (et) 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks
CA2310888A1 (en) Monoclonal human natural antibodies
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
MA26685A1 (fr) Derives d'azetidine leur preparation et les medicaments les contenant
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
ID28003A (id) Turunan-turunan adamantana
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69028671D1 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
FR2707882B1 (fr) Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
EE03111B1 (et) Glükokortikosteroidi epimeerid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
EE200000587A (et) Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis
IL81370A (en) Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
AU9363398A (en) Hepatitis c receptor protein cd81
DE69520870D1 (de) Esculetin Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellung
HUT77004A (hu) Antiaritmiás szerekként felhasználható nitro-benzamidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
ATE198481T1 (de) Bizyclische tachykinin-antagonisten, deren herstellung und deren verwendung in pharmazeutischen zusammmensetzungen
FI955614A0 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi,niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisäl tävä lääkeaine
NO305792B1 (no) Substituerte benzensulfonylureaer, deres anvendelse for fremstilling av farmas°ytiske preparater og medikamenter inneholdende disse
IS4733A (is) Ný LH-RH mótlyf, framleiðsla þeirra og notkun, ásamt læknislyfjum sem innihalda samsetningarnar og framleiðsla þeirra
EE200200142A (et) Heterotsükliliselt asendatud bensoüülguanidiinid,nende saamine ja kasutamine ravimite valmistamiseks ning neid sisaldav ravim

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20020112